Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Latest News about ESALY Recent news which mentions ESALY < Previous 1 2 3 4 Next > Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why April 24, 2024 Tickers BIIB ESALY NEWS Tags Large Cap Biotech Health Care From Benzinga European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab March 22, 2024 Tickers BIIB ESALF ESALY NEWS Tags Stories That Matter ESALF Briefs From Benzinga Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision March 08, 2024 Tickers BIIB ESALY LLY NEWS Tags Large Cap Biotech Health Care From Benzinga Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says February 14, 2024 Tickers BIIB ESALY NEWS NVS Tags Biotech Large Cap Health Care From Benzinga Why Is Biogen Stock Trading Lower On Tuesday? February 13, 2024 Tickers BIIB ESALY NEWS Tags BIIB Health Care Large Cap From Benzinga Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns January 12, 2024 Tickers BIIB DGX ESALY LH Tags News DGX ESALY From Benzinga Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer December 08, 2023 Tickers ESALF ESALY MRK Tags MRK Market News Benzinga From Benzinga Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others November 21, 2023 Tickers ACIU BIIB ESAIY ESALY Tags Benzinga Penny Stocks LLY From Benzinga Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides November 08, 2023 Tickers BIIB ESALY Tags Guidance why it's moving News From Benzinga Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage October 13, 2023 Tickers BIIB ESALF ESALY LLY Tags General Government Briefs From Benzinga Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready October 11, 2023 Tickers BIIB DGX ESALY LH Tags RHHVF RHHBF ESALY From Benzinga LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly October 10, 2023 Tickers BIIB ESALF ESALY LLY Tags Market News LLY Benzinga From Benzinga Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories September 25, 2023 Tickers AA AAPL AMZN BIIB Tags TSN AMZN GOOG From Benzinga Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi September 25, 2023 Tickers BIIB ESALF ESALY Tags Benzinga ESALF Market News From Benzinga Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer September 22, 2023 Tickers ESALF ESALY MRK Tags Biotech Large Cap Health Care From Benzinga Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial August 25, 2023 Tickers ESALF ESALY MRK Tags General Briefs News From Benzinga Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. August 01, 2023 Tickers BIIB ESALY RETA Tags ESALY Market News RETA From Motley Fool Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts July 07, 2023 Tickers BIIB ESALF ESALY Tags Benzinga Trading Ideas Analyst Ratings From Benzinga Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed June 14, 2023 Tickers BIIB ESALY Tags Market News Benzinga ESALY From Benzinga FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories June 13, 2023 Tickers AAPL ATVI BEP BIIB Tags UAL JTKWY DUK From Benzinga Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources June 13, 2023 Tickers BIIB ESALF ESALY Tags Benzinga Market News BIIB From Benzinga Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote June 12, 2023 Tickers BIIB ESALF ESALY Tags News Briefs Movers From Benzinga Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low June 12, 2023 Tickers BIIB ESALY ILMN KDNY Tags BIIB Equities Futures From Benzinga Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' June 08, 2023 Tickers BIIB ESALF ESALY Tags ESALF Briefs News From Benzinga Amazon Considers Launching Ad-Supported Prime Video Tier, Google & Microsoft Face Backlash For Ad Inclusion In AI Trials, Airbus Records One-Third Jump In May Deliveries: Today's Top Stories June 08, 2023 Tickers AMZN BLK DIS EADSY Tags Markets Top Stories GOOGL From Benzinga FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval June 08, 2023 Tickers BIIB ESALF ESALY Tags ESALF General News From Benzinga Medtronic, Merck, Williams Companies And More: CNBC's 'Final Trades' June 01, 2023 Tickers ESALY IEF MDT MRK Tags Jenny Harrington MDT Media From Benzinga After Back To Back Failure For Keytruda Plus Lenvima, Merck Touts Durable Clinical Benefit For The Combo In Advanced Kidney Cancer May 26, 2023 Tickers ESALY MRK PFE Tags General Health Care Biotech From Benzinga Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen May 04, 2023 Tickers BIIB ESALF ESALY LLY Tags Large Cap Biotech BIIB From Benzinga Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes! April 21, 2023 Tickers BIIB ESALF ESALY LLY Tags General Government Briefs From Benzinga < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.